Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2014

Yang GC, Kuhel WI, Scognamiglio T. Amyloid-rich low grade adenocarcinoma of the parotid: fine-needle aspiration cytology with histologic correlations. Diagn Cytopathol. 2014;42(9):798-801.

Gupta A, Hunt CR, Hegde ML, Chakraborty S, Chakraborty S, Udayakumar D, et al. MOF phosphorylation by ATM regulates 53BP1-mediated double-strand break repair pathway choice. Cell Rep. 2014;8(1):177-89.

Cho H, Herzka T, Zheng W, Qi J, Wilkinson JE, Bradner JE, et al. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov. 2014;4(3):318-33.

Yoo S, Pettersson A, Jordahl KM, Lis RT, Lindstrom S, Meisner A, et al. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014;23(10):2027-31.

Verdelli D, Nobili L, Todoerti K, Mosca L, Fabris S, D'Anca M, et al. Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line. Genes Chromosomes Cancer. 2014;53(2):154-67.

Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, et al. Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014;20(7):1873-83.

Magro CM, Wang X, Subramaniyam S, Darras N, Mathew S. Cutaneous double-hit B-cell lymphoma: an aggressive form of B-cell lymphoma with a propensity for cutaneous dissemination. Am J Dermatopathol. 2014;36(4):303-10.

Heymann JJ, Bulman WA, Maxfield RA, Powell CA, Halmos B, Sonett J, et al. Molecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples. Cytojournal. 2014;11:12.

DeSimone RA, Ginter PS, Chen Y-. Granular cell tumor of the breast eliciting exuberant pseudoepitheliomatous hyperplasia. Int J Surg Pathol. 2014;22(2):156-7.

Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014;4(5):546-53.